Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H23F3N4O2 |
Molecular Weight | 468.4709 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C1=CC=C(\C=C\C2=NC(COC3=CC=C(CCCCN4C=CN=N4)C=C3)=CO2)C=C1
InChI
InChIKey=ZTFBIUXIQYRUNT-MDWZMJQESA-N
InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
Molecular Formula | C25H23F3N4O2 |
Molecular Weight | 468.4709 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.hoelzel-biotech.com/media/import/pdf_manual/Selleckchem//S2216-10__Manual.pdf
https://www.ncbi.nlm.nih.gov/pubmed/16771730
http://adisinsight.springer.com/drugs/800019257
Curator's Comment: description was created based on several sources, including:
http://www.hoelzel-biotech.com/media/import/pdf_manual/Selleckchem//S2216-10__Manual.pdf
https://www.ncbi.nlm.nih.gov/pubmed/16771730
http://adisinsight.springer.com/drugs/800019257
TAK-165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Mubritinib displays > 4000-fold selectivity over other tyrosine kinases, such as EGFR, FGFR, PDGFR, Jak1, Src and Blk. A Phase I study to investigate a safe dose of Mubritinib, once daily (QD), in patients with tumors known to express HER2 (Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm) has been completed, but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.
Originator
Sources: http://adisinsight.springer.com/drugs/800019257
Curator's Comment: # Takeda
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16771730 |
6.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00034281
Starting dose of TAK-165 10 mg, tablets, once daily with dose escalation to tolerability for 56 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16771730
To evaluate TAK-165 sensitivity in vitro, after cells weretreated with TAK-165 at various concentrations continu-ously for 3 days. TAK-165 sensitivity depends on HER2 levels of each cellline. Especially, BT474 cells which over-express HER2strongly was highly sensitive (IC50 0.005 µmol/L) and PC-3 cells which express HER2 very weakly was less sensitive(IC50 4.62 µmol/L). But, HT1376 and ACHN cells thatover-expressed EGFR showed high IC50 (IC50 > 25 µmol/L).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:24:41 GMT 2023
by
admin
on
Fri Dec 15 16:24:41 GMT 2023
|
Record UNII |
V734AZP9BR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2167
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
V734AZP9BR
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
8446
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
6444692
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL1614707
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
C66212
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
Mubritinib
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
DTXSID501026014
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
DB12682
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
PP-49
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
SUB193705
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
366017-09-6
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY | |||
|
100000178103
Created by
admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|